World Thrombosis Day 13 October 2021: Reduce APS Knowledge Gap
Time Posted ：2024-04-03
Antiphospholipid syndrome (APS) is linked to one-third of new strokes occurring in individuals younger than 50 years, and may be responsible for up to 1% of all thrombosis. APS is a life-threatening systemic autoimmune disease that causes excessive blood clotting. Immune system mistakenly produces antibodies (antiphospholipid antibodies [aPL]) against certain normal proteins in the blood. These antibodies can cause potentially fatal events such as strokes, heart attacks, and blood clots in the legs (deep vein thrombosis) and lungs (pulmonary embolism). Antiphospholipid Syndrome is the most important treatable cause of recurrent miscarriage; it is also associated with other pregnancy complications such as pre-eclampsia, low weight babies, and premature births. Despite increased recognition of APS, much remains to be learned about the cause, full range of symptoms, diagnosis, and treatment for APS. APS can be detected by antiphospholipid (aPL) antibodies, including lupus anticoagulant (LA), anticardiolipin (aCL) antibody, and/or anti-β2 glycoprotein I (aβ2 GPI) antibody assays. APL antibodies can assist the determination of the risk of thrombotic and obstetric events, and consequently the intensity of treatment.
View Details
YHLO launched its latest iFlash integrated system at CMEF, reaching new milestone with our persistence in R&D
Time Posted ：2024-04-03
October 13, 2021, Shenzhen, China, YHLO grandly showed up at the China International Medical Equipment Fair(CMEF), brought another new high-end product iFlash 9000 to the spotlight.
CMEF is recognized as the largest scale and most well-know expo fair in China for MedTech, it attracts over 100,000 professional visitors to participate every year. Annually numbers of enterprises, dealers and agencies , medical doctors and experts, etc. are joining together in this big event from all over the world.
View Details
World Osteoporosis Day 20 October 2021: Take Action for Bone Health
Time Posted ：2024-04-03
World Osteoporosis Day is observed annually on 20 October, and launches a year-long campaign dedicated to raising global awareness of the prevention, diagnosis and treatment of osteoporosis and metabolic bone disease. We should insist on early prevention from lifestyle, and middle-aged and elderly people should be diagnosed and treated early. Pain, hunchback, reduced height and fractures are characteristic manifestations of osteoporosis, but there are many patients with osteoporosis who often have no obvious sensation in the early stages of the disease. Fractures are a direct consequence of osteoporosis, affecting the function of the body in mild cases and causing disability or even death in severe cases, with common fracture sites being the thoracolumbar spine, hip and arm.
View Details
YHLO Joined Hands With Peking University In Molecular Diagnosis
Time Posted ：2024-04-03
Recently, YHLO has signed an agreement with Peking University (one of the historic and prestigious universities worldwide) to establish a collaborative laboratory for molecular diagnosis of infectious diseases to carry out R&D in the field of liver diseases diagnostics. This significant cooperation with Peking University will leverage the advantages of its medical disciplines and talents to conduct researches on molecular diagnosis of infectious diseases, which focuses on the latest technologies and innovative products in the IVD industry, which will make the joint lab an international advanced technology research and industrialization base.
View Details
YHLO received its first IVDR, paving the way for EU IVD market
Time Posted ：2024-04-03
In this October, YHLO proudly announced that it has received its first IVDR Certificate from BSI, one of the most reputable notified bodies under the In Vitro Diagnostics Regulation (IVDR). The certificate covers Anti-TPO—a Thyroid Peroxidase Antibody Assay Test Kit, PCT—A Procalcitonin Assay Test Kit and etc., which are applied to Chemiluminescence Immunoassay platform.
View Details
One more YHLO - Beckman Coulter joint automation system installed
Time Posted ：2024-04-03
Recently, another installation of YHLO iModules system with Beckman Coulter Power Express clinical lab automation systems was perfectly completed in the Sixth Hospital of Wuhan, Hubei Province, China. This integrated Total Laboratory Automation (TLA) will boost the efficiency of daily workload in the hospital's laboratory.
View Details
Great inheritance of YHLO iFlash Series, new product being installed
Time Posted ：2024-04-03
The newly launched YHLO iFlash family member, iFlash 9000, has caught much attention in China’s in vitro diagnostic market. In only a few days after launching, the first iFlash 9000 has been successfully installed and put into operation in a large class A hospital in Jiangsu Province, China.
View Details
YHLO Showcased Its Latest iFlash CLIA at MEDICA 2021
Time Posted ：2024-04-03
From 15-18 November, YHLO is making a grand exposure at MEDICA 2021, with its latest chemiluminescence immunoassay (CLIA) analyzer iFlash 1200, the bench-top analyzer iFlash 1800, the mono-test CLIA analyzer iStar 500, and total solutions for SARS-CoV-2 on exhibition.
View Details
Add: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China
